The report offers detailed coverage of Cabazitaxel industry and main market trends. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Cabazitaxel by geography. The report splits the market size, by volume and value, on the basis of application type and geography.
Cabazitaxel (previously XRP-6258, trade name Jevtana) is a semi-synthetic derivative of a natural taxoid. It was developed by Sanofi-Aventis and was approved by the U.S. FDA for the treatment of hormone-refractory prostate cancer on June 17, 2010. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.
Global cabazitaxel production regions are mainly distributed in USA and Europe. There is no doubt that USA is the largest production region in the world. In the future, we predict that there will be more and more cabazitaxel suppliers as soon as Sanofi\'s Cabazitaxel patent expired. By 2024, global production will be 1427.4 Kg.
Currently, there are four major cabazitaxel API suppliers globally, including Sanofi, Tapi Teva, Fuan Pharmaceutical Group and Fujian Yewpark Biological etc. Sanofi is the global leader in this industry. According to our research, Sanofi had provided 845.8 Kg cabazitaxel API in 2017, which account for 95.32% of global market.
The report forecast global Cabazitaxel market to grow to reach xxx Million USD in 2020 with a CAGR of xx% during the period 2021-2025.
First, this report covers the present status and the future prospects of the global Cabazitaxel market for 2015-2025.
And in this report, we analyze global market from 5 geographies: Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia], Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland], North America[United States, Canada, Mexico], Middle East & Africa[GCC, North Africa, South Africa], South America[Brazil, Argentina, Columbia, Chile, Peru].
Key Companies
Sanofi
Tapi Teva
Fuan Pharmaceutical Group
Fujian Yewpark Biological
At the same time, we classify Cabazitaxel according to the type, application by geography. More importantly, the report includes major countries market based on the type and application.
Market Segment as follows:
Market by Order Type
Type I
Type II
Market by Application
Age Below 65
Age Above 65
By Region
Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia]
Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
North America[United States, Canada, Mexico]
Middle East & Africa[GCC, North Africa, South Africa]
South America[Brazil, Argentina, Columbia, Chile, Peru]
The research provides answers to the following key questions:
• What is the estimated growth rate and market share and size of the Cabazitaxel market for the forecast period 2021 - 2025?
• What are the driving forces in the Cabazitaxel market for the forecast period 2021 - 2025?
• Who are the prominent market players and how have they gained a competitive edge over other competitors?
• What are the market trends influencing the progress of the Cabazitaxel industry worldwide?
• What are the major challenges and threats restricting the progress of the industry?
• What opportunities does the market hold for the prominent market players?